Abstract 53P
Background
Breast cancer is the predominant malignancy in Indonesia, as per recent data from The Global Cancer Observatory (GLOBOCAN) 2020. Employing a multifaceted therapeutic approach has curbed breast cancer patient mortality. Radiotherapy's pivotal role in comprehensive breast cancer care underscores its significance. This study marks the inaugural effort to assess radiotherapy utilization rate (RUR) among Indonesian breast cancer patients.
Methods
Secondary data were gathered from breast cancer patients diagnosed within Indonesian radiotherapy centers during 2019-2021. The primary goal was a pre-pandemic evaluation of radiotherapy utilization. After rigorous data cleansing, involving duplicate elimination, meticulous analysis ensued. This unveiled actual RUR (aRUR) and optimal RUR (oRUR) for this cohort. Comparative RUR assessment with global counterparts complemented the analysis.
Results
This study encompassed 11,037 breast cancer patients from 34 Indonesian radiotherapy centers. Of these, 96.8% were female, with a minority (2.6%) being male. Notably, 60.38% were diagnosed at advanced stages (Stages 3 and 4), mirroring developing nation trends. 17 radiotherapy centers met the criteria for aRUR analysis, resulting in 26.2%. For oRUR, 9 centers were suitable, indicating 66.3% (50.7% - 78.2%). Consequently, unmet RUR needs in Indonesian breast cancer patients stood at 60.4% (48.3% - 66.4%). Data from Australia's Cancer Collaboration for Cancer Outcomes, Research & Evaluation (CCORE) 2013 exhibited a higher oRUR of 83.5% (82.5% - 84.6%), attributed to significant stage distribution differences.
Conclusions
The underutilization of radiotherapy for Indonesian breast cancer patients persists. A notable disparity between oRUR and aRUR remains. Given these outcomes, imperative next steps entail delving into underlying factors fueling this gap and devising targeted strategies to mitigate the concern.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract